Symbols

ATHE

Alterity·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATHE

Alterity Therapeutics Limited

An Australian biopharmaceutical company specializing in the treatment of neurological diseases

Industry

Biological Technology

Established Date

11/11/1997

Listing Date

09/05/2002

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

06-30

Website

www.alteritytherapeutics.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Level 14, 350 Collins Street, Melbourne, VIC 3000, Australia

Business

The company's business is to develop treatments for age-related diseases

Introduction

Alterity Therapeutics Limited was incorporated under the laws of the Commonwealth of Australia on 11 November 1997. The company is developing first-in-class therapies for the treatment of neurodegenerative diseases. The company's lead drug candidate, ATH 434 (formerly PBT 434), is the first of a new generation of small molecules designed to block the accumulation and aggregation of α-synuclein. Alpha-synuclein, when aggregated in the brain, is a pathological marker of Parkinson's disease and is considered an important biological target for the treatment of these neurodegenerative diseases.